SCHEMBL4776980

SCHEMBL4776980

N[C@H](Cc1cccc([N+](=O)[O-])c1)CN1Cc2ccccc2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 3/20 0.49
MAPT P10636 2/20 0.49
ALDH1A1 P00352 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
SIGMAR1 Q99720 2/20 0.44
TSHR P16473 1/20 0.44
PRMT5 O14744 1/20 0.42
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRM4 Q14833 1/20 0.41
POLB P06746 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX1 P07099 1/20 0.41
OPRK1 P41145 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4904700 0.78 HDAC8 (0.66) KMT2AKDM4EMEN1MAPTGRM8
SCHEMBL4904692 0.78 HDAC8 (0.66) KMT2AKDM4EMEN1MAPTGRM8
SCHEMBL4730009 0.78 EPHX1 (0.55) KMT2AMEN1SIGMAR1EPHX1
SCHEMBL30239684 0.78 DPP4 (0.44) KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL30762196 0.77 TSHR (0.56) KMT2AKDM4EMEN1MAPTALDH1A1
SCHEMBL16836911 0.76 TSHR (0.54) ALDH1A1TSHRGRM8GRM6GRM4
SCHEMBL6188426 0.76 TSHR (0.54) ALDH1A1TSHRGRM8GRM6GRM4
SCHEMBL30537970 0.76 TSHR (0.54) ALDH1A1TSHRGRM8GRM6GRM4
SCHEMBL6191530 0.76 TSHR (0.54) ALDH1A1TSHRGRM8GRM6GRM4
SCHEMBL6961010 0.74 TAAR1 (0.57) KMT2AKDM4EMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed